Related references
Note: Only part of the references are listed.Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes
Marcel Smid et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Genome profiling of ERBB2-amplified breast cancers
Fabrice Sircoulomb et al.
BMC CANCER (2010)
Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer
Sejal S. Shah et al.
HUMAN PATHOLOGY (2010)
High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
Johan Staaf et al.
BREAST CANCER RESEARCH (2010)
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
Goran Jonsson et al.
BREAST CANCER RESEARCH (2010)
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
Matteo Brunelli et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
Maria Grazia Tibiletti et al.
HUMAN PATHOLOGY (2009)
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
Alfredo Santinelli et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
HER2 gene status in primary breast cancers and matched distant metastases
Coya Tapia et al.
BREAST CANCER RESEARCH (2007)
Interphase FISH as a new tool in tumor pathology
M. G. Tibiletti
CYTOGENETIC AND GENOME RESEARCH (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Intratumoral heterogeneity of HER-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray
Sandra J. Shin et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining
JT Lewis et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Specificity of interphase fluorescence in situ hybridization for detection of chromosome aberrations in tumor pathology
MG Tibiletti
CANCER GENETICS AND CYTOGENETICS (2004)
A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization
SF Paternoster et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)